Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
Autor: | Ana Godoy-Ortiz, Alfonso Sanchez-Muñoz, Maria Rosario Chica Parrado, Martina Álvarez, Nuria Ribelles, Antonio Rueda Dominguez, Emilio Alba |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Cancer Research intrinsic subtype Disease Review Biology lcsh:RC254-282 03 medical and health sciences Basal (phylogenetics) 0302 clinical medicine Breast cancer breast cancer Internal medicine medicine HER2 Amplification Effective treatment molecular skin and connective tissue diseases neoplasms Retrospective cohort study Luminal a medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens HER2-positive 030104 developmental biology 030220 oncology & carcinogenesis HER2-enriched heterogeneity Primary breast cancer |
Zdroj: | Frontiers in Oncology, Vol 9 (2019) Frontiers in Oncology |
Popis: | The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer progression, creating a significant variability within primary tumors as well as between the primary breast cancer and their metastases, a hypothesis have already demonstrated in retrospective studies (1). A clear example of this is the HER2-positive breast cancer. In these tumors, we can find all of the transcriptional subtypes of breast cancer, even the basal like or luminal A subtypes. Although the HER2-enriched is the most representative transcriptional subtype in the HER2-positive breast cancer, we can find it too in breast cancers with HER2-negative status. This intrinsic subtype shows a high expression of the HER2 and is associated with proliferation-related genes clusters, among other features. Therefore, two hypotheses can be suggested. First, the HER2 amplification can be a well-defined driver event present in all of the intrinsic subtypes, and not a subtype marker isolated. Secondly, HER2-enriched subtype can have a distinctive transcriptional landscape independent of HER2 amplification. In this review, we present an extensive revision about the last highlights and advances in clinical and genomic settings of the HER2-positive breast cancer and the HER2-enriched subtype, in an attempt to improving the knowledge of the underlying biology of both entities and to explaining the intrinsic heterogeneity of HER2-positive breast cancers. |
Databáze: | OpenAIRE |
Externí odkaz: |